Tekmira Pharmaceuticals Corp. began limited GMP manufacture of a new RNAi therapeutic specifically targeting the Ebola Guinea variant, which is the viral variant responsible for the Ebola epidemic currently prevalent in West Africa. Supply of the new product will be available in early December 2014 for potential use by various collaborators. The company will provide updates as definitive agreements are established.   The FDA previously authorized the company to provide TKM-Ebola for treatment un...